Senior couple relaxing in garden

Respiratory Syncytial Virus (RSV) Vaccine Study

Ages

60 - 85 years old

Location

Phoenix, AZ

Compensation

Up to $1,600
Senior couple relaxing in garden

Respiratory Syncytial Virus (RSV) Vaccine Clinical Trials in Phoenix

Centricity Research is currently participating in a respiratory syncytial virus (RSV) vaccine study at our Phoenix, Arizona location. Severe infection with RSV can lead to pneumonia and bronchiolitis and may require hospital care. People at greatest risk of severe infection are the very young (those less than six months old), those over the age of 65, and those of any age who have heart or lung conditions or a weakened immune system. RSV can also make existing heart and lung problems worse.

Enroll Now

Consider the VANIR Research Study for RSV

The primary objective of the VANIR clinical trial is to evaluate the effectiveness and safety of an investigational respiratory syncytial virus (RSV) vaccine in healthy adults. You may qualify for this study if you are:

  • 60 years of age or older
  • Healthy or have one or more chronic medical conditions, including mild to moderate underlying illnesses such as chronic cardiac diseases, lung disease, congestive heart failure, hypertension, and type 2 diabetes mellitus
  • Willing and able to use a smartphone or tablet application to record information during the study

AND

  • Have not received any other licensed or investigational RSV vaccine preceding the trial vaccination

As a part of our ongoing commitment to protect your health and safety, we’re practicing enhanced safety measures at our clinical research sites.

Ready to Volunteer?

Volunteer today to see if you qualify for our respiratory syncytial virus (RSV) vaccine clinical research study. Qualified volunteers may be compensated for time and travel.